In The Spotlight


baush.jpg Shares of Bausch Health Companies Inc. (BHC), formerly known as Valeant Pharmaceuticals International Inc., are up 35% since the start of this year.

biotechipo-feb04.jpg Anchiano Therapeutics, formerly known as Biocancell, is a clinical-stage biotechnology company developing a targeted gene therapy to improve the standard treatment for early-stage bladder cancer.

beattouches-feb05.jpg Shares of BioTelemetry Inc. (BEAT) have been hitting new highs, thanks to the string of strong quarterly results. The stock closed at an all-time high of $76.50 yesterday, and that represents a gain of 30% in just a month.

biotechipo-feb04.jpg Harpoon Therapeutics, Inc. is a clinical-stage an immuno-oncology company, and its proprietary antibody-based drug discovery platform is called TriTAC, which offers a new way to unleash the target cell-killing properties of a patient's own immune system.

assembly-jan29.jpg Shares of Assembly Biosciences Inc. (ASMB) are down nearly 69% from their 52-week high of $67.36 recorded on March 13, 2018.

avro-jan22.jpg Shares of AVROBIO Inc. (AVRO) have lost 39% of their value over the last 1 month in sharp contrast to the iShares Nasdaq Biotechnology ETF (IBB) index which has gained 8% during the same period.

pharma-022218_14jan19.jpg Shares of Innoviva Inc. (INVA), which recently touched a new 52-week high of $19.82, are up 12% so far this month, slightly lagging behind the iShares NASDAQ Biotechnology Index (ETF) (IBB), which has gained 14% during the same period.

axonics-jan07.jpg Axonics Modulation Technologies Inc. (AXNX), which recently made its debut on the NASDAQ, is down nearly 2% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) has gained nearly 8% for the same period.

fleurstat-dec20.jpg Starpharma (SPHRY.OB), on Thursday, announced that it has licensed the sales and marketing rights of VivaGel BV in the United States to ITF Pharma, a subsidiary of Italfarmaco S.p.A, a privately held European specialty pharmaceutical company.

bank-dec18.jpg 2018 has been a banner year for healthcare IPOs in the U.S. - with more than 80 companies making a debut on the bourses compared to 50 in 2017. Let's take a look at some of the healthcare IPOs of 2018 that have delivered more than 50% returns.

achn-dec11.jpg Achillion Pharmaceuticals Inc. (ACHN), which is slated to report clinical data next week, has gained 7% so far this month.

osmotica-dec3.jpg Osmotica Pharmaceuticals plc (OSMT), which recently made its debut on the Nasdaq, is down 12% since its IPO while the iShares Nasdaq Biotechnology ETF (IBB) index has lost nearly 5% of its value for the same period.

catalyst-nov28.jpg Shares of Catalyst Pharmaceuticals Inc. (CPRX) have lost 26% of their value so far this year while the iShares Nasdaq Biotechnology ETF (IBB) has fallen about 2.6% during the same period.

nicord-nov22.jpg Shares of Gamida Cell Ltd. (GMDA) are up nearly 15% this month while the iShares Nasdaq Biotechnology ETF index (IBB) is down 1.55% for the same period.

cannabisleaf-nov19.jpg Of late, cannabis-related news and stocks have been garnering a lot of investor attention. Let's take a look at some of them.

Follow RTT